Rybelsus 7 (Semaglutide) 7 mg Tablets

Rybelsus is manufactured as oral tablets:

• Dosage Form & Packaging: 1 blister card containing 10 tablets, packed in a protective cardboard box.
• Active Ingredient: Semaglutide — 7 mg per tablet.
• Excipients: Salcaprozate sodium (SNAC — absorption enhancer), microcrystalline cellulose, povidone K90, magnesium stearate.

Pharmacodynamics: Semaglutide is a selective GLP-1 receptor agonist. It stimulates glucose-dependent insulin secretion while suppressing glucagon release. Additionally, it slows gastric motility, prolonging postprandial fullness and lowering calorie intake.

Pharmacokinetics: The SNAC excipient facilitates stomach absorption of the semaglutide peptide. Peak concentration occurs within 1–3 hours post-dose. The elimination half-life is approximately 1 week, maintaining steady plasma levels.

Rybelsus 7 mg is indicated for:

• 🔹 Type 2 Diabetes Mellitus: Monotherapy (when metformin is inappropriate) or in combination with other anti-diabetic medications in adults.
• 🔹 Weight Management (Off-label): Used as a maintenance or dose-escalation step for chronic weight management in overweight or obese patients.
• 🔹 Veterinary Use: Contraindicated. Not used in cats or dogs due to severe risks of hypoglycemia, acute pancreatitis, and GI toxicity.

Administration guidelines for Rybelsus:

• 👤 For Humans: Take 1 tablet once daily on an empty stomach immediately upon waking. Swallow whole with a plain sip of water (no more than 120 ml). Wait at least 30 minutes before eating, drinking, or taking other oral medications. The 7 mg dose is a maintenance step following the initial 3 mg daily dose for 30 days.
• 🐾 For Animals: Do not use. No established veterinary doses or safety protocols exist for domestic pets.

Rybelsus is contraindicated in:

• ❌ Hypersensitivity to semaglutide or any excipients.
• ❌ Personal or family history of Medullary Thyroid Carcinoma (MTC) or MEN 2 syndrome.
• ❌ Type 1 diabetes mellitus or diabetic ketoacidosis.
• ❌ Pregnancy, planned pregnancy, or breastfeeding.
• ❌ Pediatric patients under 18 years of age.

Consider the following drug interactions for Rybelsus:

• ⚠️ Oral Medications: Delayed gastric emptying may alter the absorption rate of concomitantly administered oral drugs (e.g., levothyroxine).
• ⚠️ Insulin & Sulfonylureas: Concomitant use increases the risk of hypoglycemia; dosage adjustments may be required.

Strictly contraindicated during pregnancy and lactation. Discontinue Rybelsus at least 2 months prior to a planned pregnancy due to the long half-life of semaglutide.

Potential side effects of Rybelsus:

• 🤢 Gastrointestinal: Nausea, vomiting, diarrhea, constipation, eructation, abdominal discomfort (usually subsides over time).
• ⚠️ Systemic/Metabolic: Decreased appetite, fatigue, dizziness, rare cases of acute pancreatitis or hypoglycemia.

Symptoms: Severe nausea, intractable vomiting, and marked hypoglycemia.

Treatment: No specific antidote. Provide supportive care and administer oral or intravenous glucose if hypoglycemia occurs.

Storage instructions for Rybelsus:

• 🌡️ Temperature: Store in the original package at temperatures below 30 °C.
• 💧 Moisture: Keep in the original blister card to protect from moisture and light. Do not transfer to pillboxes.
• 👶 Safety: Keep out of reach of children and pets.

Authenticity features of original Rybelsus:

• 🛡️ Branding & Logo: Official blue Novo Nordisk Apis bull logo on packaging. Red-orange side gradient panel featuring a sun motif.
• 🔍 Batch Details: Dosage (7 mg in red badge), Batch No., Exp. Date, and 2D barcode clearly printed on carton and blister.
• 📦 Packaging: White and red carton containing 1 blister card with 10 oval, white to light-yellow tablets.